![Rajiv Amin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rajiv Amin worked as a Senior Director of Financial Reporting at Alvogen, Inc. and Kyowa Kirin, Inc. He also worked as a Controller-Americas at Convatec Group Plc.
Amin received his undergraduate degree from the University of Scranton and his graduate degree from Babson College.
| Sociétés | Poste | Fin |
|---|---|---|
Alvogen, Inc.
 Alvogen, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Corporate Officer/Principal | - |
Kyowa Kirin, Inc.
 Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Corporate Officer/Principal | - |
| CONVATEC GROUP PLC | Corporate Officer/Principal | - |
| IPI LEGACY LIQUIDATION CO | Directeur Financier/CFO | 10/05/2023 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 6 |
|---|---|
Impel Pharmaceuticals, Inc.
 Impel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a late-stage biopharmaceutical company focused on developing transformative therapies for central nervous system disorders | Health Technology |
Babson College
 Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Scranton
 University of Scranton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alvogen, Inc.
Alvogen, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Convatec Group Plc
 Convatec Group Plc Medical SpecialtiesHealth Technology Develops, manufactures, and markets medical products and technologies | Health Technology |
Kyowa Kirin, Inc.
Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
